In addition, NR1H3 was highly expressed in pathological responders receiving FEC (Fluorouracil, Epirubicin, Cyclophosphamide) treatment in grade 1 breast cancer patients and Ixabepilone treatment in HER2 negative patients (Supplementary Figures S15C,D). Here, ERBB2 is linked to breast carcinoma.